Axsome Therapeutics Inc (MIL:1AXSM)
€ 214.7 -1.5 (-0.69%) Market Cap: 11.06 Bil Enterprise Value: 10.99 Bil PE Ratio: 0 PB Ratio: 225.46 GF Score: 31/100

Axsome Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 19, 2026 / 05:35PM GMT
Release Date Price: €195.25
Leonid Timashev
RBC Capital Markets Inc - Equity Analyst

All right. Thanks, everyone, for being here. Happy to have our first session after our keynote and lunch here with Axone, represented by Mark Jacobson and Nick Pizzie. So thanks for being here.

Mark Jacobson Axsome Therapeutics Inc;Chief Operating Officer

Thanks for having us. Yeah, we're happy to be here. Thanks, Leo.

Questions & Answers

Leonid Timashev
RBC Capital Markets Inc - Equity Analyst

Great. So a lot of exciting developments lately with the company. So there's a lot to talk about, but maybe we can start off with the approval in Alzheimer's agitation recently came through. Maybe just by way of introduction, you can sort of remind us of.

Differentiation the drug offers and maybe weaving in now that you have a label, sort of how that met or exceeded your expectations and how you're feeling about that going forward.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot